UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

The lancet oncology, 2011-09, Vol.12 (9), p.841-851

2011

Link zum Volltext

Verfügbarkeit prüfen

State of the Art in CML: Update

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S151-S152

Hochhaus, Andreas

2021

Link zum Volltext

Verfügbarkeit prüfen

BCR-ABL mutations in chronic myeloid leukemia

Hematology/oncology clinics of North America, 2011-10, Vol.25 (5), p.997

2011

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial

International journal of radiation oncology, biology, physics, 2009-08, Vol.74 (5), p.1487-1493

2009

Link zum Volltext

Verfügbarkeit prüfen

KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer

International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.1032-1038

2011

Link zum Volltext

Verfügbarkeit prüfen

Clinical resistance to imatinib: mechanisms and implications

Hematology/oncology clinics of North America, 2004-06, Vol.18 (3), p.641

2004

Link zum Volltext

Verfügbarkeit prüfen

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression

Seminars in oncology, 2012-02, Vol.39 (1), p.58-66

2012

Link zum Volltext

Verfügbarkeit prüfen

JAK2 -V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

The lancet oncology, 2007-07, Vol.8 (7), p.658-660

2007

Link zum Volltext

Verfügbarkeit prüfen

Combined Adjuvant Radiochemotherapy With IMRT/XELOX Improves Outcome With Low Renal Toxicity in Gastric Cancer

International journal of radiation oncology, biology, physics, 2009-11, Vol.75 (4), p.1187-1195

2009

Link zum Volltext

Verfügbarkeit prüfen

CML - Not only BCR-ABL1 matters

Best practice & research. Clinical haematology, 2020-09, Vol.33 (3), p.101194-101194, Article 101194

2020

Link zum Volltext

Verfügbarkeit prüfen

Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial

International journal of radiation oncology, biology, physics, 2009, Vol.73 (1), p.142-147

2009

Link zum Volltext

Verfügbarkeit prüfen

Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients

Leukemia research, 2016-09, Vol.48, p.84-91

2016

Link zum Volltext

Verfügbarkeit prüfen

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies

Cell, 2018-04, Vol.173 (2), p.470-484.e18

2018

Link zum Volltext

Verfügbarkeit prüfen

mRNA Expression of Platelet-Derived Growth Factor Receptor-β and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer

International journal of radiation oncology, biology, physics, 2008-12, Vol.72 (5), p.1544-1550

2008

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia

The Journal of molecular diagnostics : JMD, 2020-01, Vol.22 (1), p.81-89

2020

Link zum Volltext

Verfügbarkeit prüfen

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression : MOLECULAR PATHOGENESIS OF HEMATOLOGIC MALIGNANCIES

Seminars in oncology, 2012, Vol.39 (1), p.58-66

2012

Link zum Volltext

Verfügbarkeit prüfen

Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer

Complementary therapies in medicine, 2018-12, Vol.41, p.105-110

2018

Link zum Volltext

Verfügbarkeit prüfen

Cytogenetic and molecular mechanisms of resistance to imatinib

Seminars in hematology, 2003-04, Vol.40 (2), p.69-79

Hochhaus, Andreas

2003

Link zum Volltext

Verfügbarkeit prüfen

POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S178-S178

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S179-S179

2023

Link zum Volltext

Verfügbarkeit prüfen

CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S349-S350

2023

Link zum Volltext

Verfügbarkeit prüfen

CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S345-S345

2023

Link zum Volltext

Verfügbarkeit prüfen

Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner

Journal of magnetism and magnetic materials, 2021-03, Vol.521, p.167535, Article 167535

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(106)
Berichte
(1)

Sprache

Englisch
(107)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Humans
(33)
Hematology, Oncology And Palliative Medicine
(29)
Oncology
(23)
Cml
(17)
Hematology
(17)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(13)
Middle Aged
(13)
Chronic Myeloid Leukemia
(12)
Female
(12)
Male
(12)
Aged
(10)
Fusion Proteins, Bcr-Abl - Genetics
(10)
Imatinib Mesylate
(10)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(10)
Adult
(9)
Benzamides
(9)
Tki
(9)
Asciminib
(8)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Complete
(57)
IngentaConnect Journals
(41)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(30)
IngentaConnect Journals
(14)
Single Journals
(11)
EZB Free E-Journals
(6)

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

State of the Art in CML: Update

BCR-ABL mutations in chronic myeloid leukemia

Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial

KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer

Clinical resistance to imatinib: mechanisms and implications

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression

JAK2 -V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

Combined Adjuvant Radiochemotherapy With IMRT/XELOX Improves Outcome With Low Renal Toxicity in Gastric Cancer

CML - Not only BCR-ABL1 matters

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial

Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies

mRNA Expression of Platelet-Derived Growth Factor Receptor-β and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression : MOLECULAR PATHOGENESIS OF HEMATOLOGIC MALIGNANCIES

Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer

Cytogenetic and molecular mechanisms of resistance to imatinib

POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

POSTER: CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors

CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors

Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner

Aktive Filter

Suchergebnisse filtern